Navigation Links
FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA for Review
Date:9/17/2010

SAN JOSE, Calif., Sept. 17 /PRNewswire/ -- Teikoku Pharma USA, Inc., an international specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for a new weekly transdermal patch of Aricept®, a leading medication for the treatment of Alzheimer's disease.

The company developed the weekly Aricept(r) patch based on a license agreement executed between Teikoku Pharma USA, Inc. and Eisai Co., Ltd. (Eisai) in February 2009. The acceptance of the NDA indicates that the FDA deems the company's submission to be sufficient to review. The NDA was submitted to the FDA by Teikoku Pharma USA, Inc. on June 30, 2010. If approved, Eisai's subsidiary, Eisai Inc., will hold marketing rights in the U.S.

The Aricept® transdermal patch formulation employs a unique drug delivery system, making it the world's first weekly transdermal patch for the treatment of Alzheimer's disease. It was developed to provide a potential new treatment option to Alzheimer's disease patients who have trouble swallowing, as well as to reduce the burden on caregivers and family members who administer medication to patients.

About Teikoku

Teikoku Pharma USA, Inc., a wholly-owned subsidiary of Teikoku Seiyaku Co., Ltd. that is a leading supplier of the topical analgesic transdermal patch, Lidoderm®, in the world, is a specialty pharmaceutical company that develops and manufactures enhanced pharmaceutical products with its transdermal drug delivery technology. Teikoku focuses its efforts on two therapeutic areas: chronic and acute pain, and the central nervous system (CNS). The company looks forward to exploring a new field of CNS with the systemic transdermal patch.  Teikoku is committed to applying its transdermal technology for the benefit of patients and partners. For more information, please visit www.teikokuusa.com.

About Eisai

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovered and developed Aricept® (Donepezil HCl tablets), the number-one prescribed Alzheimer's medication worldwide. It is sold in approximately 75 countries. In the United States, the product is co-promoted by Eisai Inc. and Pfizer Inc. and distributed by Eisai Inc. Aricept® continues to be studied for various potential new indications and formulations. Eisai focuses its efforts on three therapeutic areas: integrative neuroscience, integrative oncology, and vascular and immunology reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. For more information, please visit www.eisai.co.jp.


'/>"/>
SOURCE Teikoku Pharma USA, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Accepts Sanofi Pasteur File Submission for Novel Influenza Vaccine Delivered by Intradermal Microinjection
2. FDA Accepts Sanofi Pasteurs Application to Expand Indication of Menactra® Vaccine to Infants and Toddlers
3. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
4. FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review
5. FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
6. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
7. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
8. FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
9. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
10. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
11. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016 Global  urinalysis market ... by 2022, according to a new report by ... http://photos.prnewswire.com/prnh/20150105/723757 ) , Automation ... and accuracy delivered by the new generation urinalysis ... urinalysis instruments and consumables. For instance, the automatic ...
(Date:4/26/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO) is pleased ... Pharm D., to Vice President of Education and Quality. ... will continue to lead and oversee Diplomat University, an ... and training to Diplomat employees and external professionals on ... also houses the quality assurance department, which focuses on ...
(Date:4/26/2016)... -- Research and Markets has announced the ... report to their offering.      (Logo: ... market is projected to grow at a CAGR of ... is a technique that involves measurement and analysis of ... changes in biochemical pathways. The aim of performing these ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of ... them second place for Tampa’s Best Places to Work. They were ranked in the ... great accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We work ...
(Date:4/29/2016)... ... 29, 2016 , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) -- ... A. Potter -- are proud of the recent release of their 2014 in vitro ... SART published the latest verified data for 375 U.S. member clinics. *Preliminary data ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, Inc. recently sent representatives ... Petbiotics ™, as they fondly call them. As animal lovers, they were ... their non-profit organizations. Animal rescues across the nation face huge hurdles rescuing animals ...
(Date:4/29/2016)... ... April 29, 2016 , ... HEALTHCAREfirst , the ... services, and Deyta Analytics, recently announced the recipients of the fourth annual Hospice ... as measured from the caregiver’s point of view. The official list of recipients ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... study detailing the company’s use of Microsoft Dynamics GP for one their long-term ... a solution that integrated Dynamics GP with key clinical management systems, and delivered ...
Breaking Medicine News(10 mins):